J2KBIO제이투케이바이오

J2KBIO's trailing profits remain solid, but the share price is well below its 52-week high and the 2025 numbers were weaker than 2023.

J2KBIO, a South Korean maker of cosmetic raw materials, reported trailing twelve-month revenue of ₩43.9B and net income of ₩5.8B through H1 2026, with a net margin of 13.2% and a cash balance of ₩9.2B against ₩0.4B of borrowings. The share price closed at ₩8,820 on 2026-10-21, roughly 31% below its 52-week high of ₩12,860, and the stock is roughly flat over one year.

What stands out

• Trailing revenue of ₩43.9B is well above full-year 2025 revenue of ₩33.0B, while 2025 operating margin fell to 8.9% from 19.7% in 2023.
• 2024 showed a net loss of ₩1.7B despite operating income of ₩3.6B, and the filings in the data do not explain the gap.
• The company's cash of ₩9.2B exceeds its borrowings, and liabilities are 18.7% of equity.
• Trailing P/E of 8.9 and P/B of 1.4 compare with much higher multiples for APR and Amorepacific, and the 2.8% dividend yield is listed in the data.
• The company's own discounted cash flow model gives a base value of ₩15,728, but this is a model output rather than a forecast or a target price.

What to watch

• The next results release, as the data contains no scheduled earnings date beyond the H1 2026 half-year report already filed on 2026-08-12.
• Foreign ownership has slipped from 2.1% to 1.8% over 60 days, and the 20-day flows show retail investors net sellers.
• Insider shareholding reports filed in May and August 2026, and the corporate value-up plan filed in March 2026, whose contents are not in the data.